Innoviva, Inc. (INVA) is a Biotechnology company in the Healthcare sector, currently trading at $24.19. It has a SharesGrow Score of 86/100, indicating a strong investment profile with 6 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of INVA = $42.36 (+75.1% from the current price, the stock appears undervalued). Analyst consensus target is INVA = $38 (+55.7% upside).
Valuation: INVA trades at a trailing Price-to-Earnings (P/E) of 6.5 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.42.
Financials: revenue is $425M, +9.3%/yr average growth. Net income is $271M, growing at +318.8%/yr. Net profit margin is 63.8% (strong). Gross margin is 72.3% (-23.5 pp trend).
Balance sheet: total debt is $269M against $1.2B equity (Debt-to-Equity (D/E) ratio 0.23, conservative). Current ratio is 14.64 (strong liquidity). Debt-to-assets is 16.5%. Total assets: $1.6B.
Analyst outlook: 5 / 10 analysts rate INVA as buy (50%) — moderate consensus.
SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 83/100 (Pass), Past 100/100 (Pass), Health 100/100 (Pass), Moat 55/100 (Partial), Future 64/100 (Pass), Income 100/100 (Pass).
